1. S. Goto1, J. Zhu2, L. Lisheng2, BH. Oh3, D. Wojdyla4, M. Hanna5, J. Horowitz6, L. Wallentin7, D. Xavier8, JH. Alexander4 (1) Tokai University School of Medicine, Isehara, Japan (2) Fuwai Hospital, Beijing, China, People's Republic of (3) Seoul National University Hospital, Seoul, Korea, Republic of (4) Duke Clinical Research Institute, Duke University Medical Center, Durham, United States of America (5) Bristol-Myers Squibb, Princeton, United States of America (6) University of Adelaide, Adelaide, Australia (7) Uppsala University, UCR-Uppsala Clinical Research Center, Uppsala, Sweden (8) St. John's Research Institute, Bangolore, India Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation in East Asia with Atrial Fibrillation

2. Global Collaboration 39 countries, 1034 sites, 18,201 patients Canada: 1057 United States: 3433 Mexico: 609 Finland: 26 Denmark: 339 Hungary: 455 Netherlands: 309 Ukraine: 956 Sweden: 217 Norway: 90 U.K.: 434 Belgium: 194 France: 35 Spain: 230 Austria: 34 Italy: 178 Israel: 344 Poland: 314 Czech Rep: 165 Chile: 258 Peru: 213 Colombia: 111 Brazil: 700 Argentina: 1561 South Africa: 89 Russia: 1800 China: 843 India: 601 South Korea: 310 Taiwan: 57 Philippines: 205 Malaysia: 126 Singapore: 40 Australia: 322 Germany: 854 Japan: 336 Romania: 274 Turkey: 6 Hong Kong: 76 Bristol-Myers Squibb and Pfizer 1,993 patients were recruited from East Asian countries including China (n=843), Japan (n=336), South Korea (n=310), Philippines(n=205), Malaysia (n=126), Hong Kong (n=76) and Singapore (n=40)

3. Primary Efficacy Endpoint

4. Primary Safety Endpoint

6. Conclusion- East Asia vs Non East Asia The ARISTOTLE trial enrolled over 1900 patients from East Asian countries. These patients were of lower body weight and tended to have poorer INR control with warfarin. Despite similar CHADS2 scores, the overall rate of stroke was higher in East Asian than non-East Asian patients. Apixaban had consistent benefits when compared with warfarin on stroke or systemic embolism in East Asian and non-East Asian patients. A tendency toward a greater reduction in bleeding was seen with apixaban compared with warfarin in East Asian compared with non- East Asian patients. Rates of intracranial bleeding on warfarin were higher in East Asian than non-East Asian patients. These data support that apixaban is an attractive alternative to warfarin among East Asian as well as non-East Asian patients with nonvalvular AF.